Clinical Trials Logo

Diseases of the Nervous System clinical trials

View clinical trials related to Diseases of the Nervous System.

Filter by:
  • None
  • Page 1

NCT ID: NCT05013944 Recruiting - Neoplasms Clinical Trials

AnovaOS Network Powered Patient Registry

Start date: September 1, 2021
Phase:
Study type: Observational [Patient Registry]

The objective of this study is the development, implementation and management of a registry of patient data that captures clinically meaningful, real-world, data on the diagnosis, nature, course of infection, treatment(s) and outcomes in patients with complex disease globally.

NCT ID: NCT04672590 Active, not recruiting - Clinical trials for Diseases of the Nervous System

COVID-19 Neurological Disease: A Prospective Study

Start date: April 20, 2021
Phase:
Study type: Observational

Background: Recent reports increasingly recognize neurological manifestations in COVID-19 patients. However, the full spectrum of the disease and risk factors are not well understood. Aim: To describe the full spectrum of neurological manifestations in COVID-19 and assess the clinical characteristics, risks and prognostic factors. Outcomes: Identification of COVID-19 associated neurological disease is the primary outcome while requirement for admission to critical care unit, mortality, length of hospital stay, quality of life, and neurological disability are the secondary outcomes. Participants: Patients above Age more than 18 years enrolled based on new-onset acute neurological disease and COVID19 positive will serve as cases while patient with confirmed COVID-19 without neurological manifestation will serve as controls. Design and Procedures: The study is prospective case control in design and is divided into three phases in India, Brazil and Malawi ; the first phase will address role of hypoxia in causation of neurological diseases, the second phase will compare characteristics of patients hospitalized with COVID-19 with and without neurological disease and the third phase will assess the long-term follow up (at 3 months and 9 months) of cases.